Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $40.03, for a total transaction of $400,300.00. Following the transaction, the chief financial officer now directly owns 101,959 shares of the company’s stock, valued at approximately $4,081,418.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jack Anders also recently made the following trade(s):
- On Monday, March 18th, Jack Anders sold 1,261 shares of Revolution Medicines stock. The stock was sold at an average price of $31.58, for a total value of $39,822.38.
Revolution Medicines Stock Up 2.6 %
Revolution Medicines stock traded up $1.01 during midday trading on Friday, hitting $40.20. 789,293 shares of the stock were exchanged, compared to its average volume of 1,362,345. Revolution Medicines, Inc. has a 52-week low of $15.44 and a 52-week high of $40.21. The business’s 50-day moving average price is $33.04 and its 200-day moving average price is $28.30. The stock has a market capitalization of $6.85 billion, a price-to-earnings ratio of -10.66 and a beta of 1.46.
Institutional Investors Weigh In On Revolution Medicines
Hedge funds have recently made changes to their positions in the business. Manchester Capital Management LLC purchased a new stake in Revolution Medicines in the fourth quarter worth $80,000. China Universal Asset Management Co. Ltd. raised its stake in Revolution Medicines by 101.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,802 shares of the company’s stock valued at $78,000 after acquiring an additional 1,409 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Revolution Medicines during the first quarter valued at about $104,000. Fred Alger Management LLC bought a new position in Revolution Medicines during the third quarter worth about $126,000. Finally, Federated Hermes Inc. purchased a new position in shares of Revolution Medicines in the third quarter worth about $126,000. 94.34% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Oppenheimer lifted their target price on Revolution Medicines from $43.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, April 12th. Piper Sandler began coverage on shares of Revolution Medicines in a research note on Monday, March 11th. They issued an “overweight” rating and a $43.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $46.00 price target (up from $36.00) on shares of Revolution Medicines in a report on Monday, April 8th. Raymond James raised shares of Revolution Medicines from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $36.00 to $48.00 in a research note on Wednesday, April 10th. Finally, Wedbush increased their price objective on shares of Revolution Medicines from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $41.20.
Get Our Latest Research Report on Revolution Medicines
About Revolution Medicines
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Articles
- Five stocks we like better than Revolution Medicines
- Best Aerospace Stocks Investing
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Stock Sentiment Analysis: How it Works
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.